News | March 01, 2010

Diagnostic Value of Heart Rate Variability Researched in Ecuador

March 1, 2010 – A collaborative agreement with the Universidad San Francisco de Quito in Ecuador and Vicor Technologies Inc. to help identify patients at risk of sudden cardiac death and autonomic nervous system dysfunction.

The agreement uses Vicor Technologies noninvasive medical devices and diagnostics using its PD2i nonlinear algorithm and software. The its PD2i Analyzer displays and analyzes electrocardiographic data to provide a measure of heart rate variability (HRV) in patients at rest, and during controlled exercise and paced respiration. The clinical significance of HRV is physician determined.

Under the terms of the agreement Vicor will collaborate with the Universidad San Francisco de Quito (USFQ) to develop academic programs that advance awareness and use of the measure of heart rate variability (HRV) to diagnose various medical disorders within a variety of health-challenged and/or at risk populations. It will also promote continued research into the uses of HRV in USFQ clinics, and stimulate assistance from Ecuador’s public and private health sectors. The goal is to prevent disease with appropriate intervention/treatment based on early diagnosis using HRV.

Additionally, Vicor will serve as the sponsor of the Vicor Technologies Inc. Heart Rate Variability Institute at the Universidad San Francisco de Quito, with the express purpose of furthering throughout Ecuador HRV research and its use as a medical diagnostic as measured with Vicor’s PD2i Analyzer.

Specifically, this collaboration will involve the Inclusion Institute, its emergency rooms, and intensive care units for applications involving patients at imminent risk of death, those with severe psychiatric illness, and those with elevated cardiovascular risk and mental illness.

This effort may also include study of HRV as measured by Vicor’s PD2i Analyzer to identify autonomic nervous system dysfunction in diabetics, the need for lifesaving intervention in trauma victims as a means of facilitating triage efforts, imminent mortality in those with brain injury, and the risk of sudden cardiac death in target populations, including young athletes.

“Science and technology have propelled knowledge and practical applications in medicine at a fantastic speed. The collaboration of several universities for the purpose of investigating the risk of sudden death in certain special groups will definitely broaden the spectrum of routine procedures that will result in the prevention of these events and the salvage of precious human lives,” said Dr. Enrique Noboa, dean, USFQ School of Medicine.

“Autonomic nervous system dysfunction and its role in disease constitute a field of continuous expansion and research,” said Dr. Michelle Grunauer, project manager, USFQ HRV Institute. “The implications of heart rate variability analysis involve several disciplines, and focus our attention in multi-causality. Furthermore, the rapid, precise, noninvasive and cost-effective stratification of risk of AD in patients admitted to the Emergency Department with the PD2i test is invaluable.”

The Universidad San Francisco de Quito is a nonprofit liberal arts university. Founded in 1988 by the Corporación de Promoción Universitaria, (its umbrella nonprofit foundation), the USFQ was the first totally private, self-financed university in Ecuador. Today, the USFQ has 16 colleges and academic institutes spread across its main campus in Cumbayá-Quito and The Galapagos Academic Institute for the Arts and Sciences in San Cristobal in the Galapagos Archipelago. Additionally, USFQ has a biodiversity research station in Tiputini and an anthropology research institute in Riobamba.

For more information:

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init